公开(公告)号：US20210338664A1

公开(公告)日：2021-11-04

申请号：US16862500

申请日：2020-04-29

Applicant: CFD Research Corporation

Inventor： Narender Singh

IPC: A61K31/497 ,  A61P1/16

Abstract: A method for providing a therapy to a subject that has been exposed to an Aflatoxin B1 can include administering a compound having a structure of Formula 1 to the subject after exposure to the Aflatoxin B1: wherein: R1, R2, R3, R4, R5 and/or R6 are each individually a chemical moiety and n is 1, 2, 3, 4, or 5. The compound can be Amprenavir or a derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof. The prodrug can be Amprenavir phosphate.

公开(公告)号：US11364239B2

公开(公告)日：2022-06-21

申请号：US16862500

申请日：2020-04-29

Applicant: CFD Research Corporation

Inventor： Narender Singh

IPC: A61K31/34 ,  A61K31/665 ,  A61K31/497 ,  A61P1/16 ,  A61K31/341 ,  A61K31/661

Abstract: A method for providing a therapy to a subject that has been exposed to an Aflatoxin B1 can include administering a compound having a structure of Formula 1 to the subject after exposure to the Aflatoxin B1: wherein: R1, R2, R3, R4, R5 and/or R6 are each individually a chemical moiety and n is 1, 2, 3, 4, or 5. The compound can be Amprenavir or a derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof. The prodrug can be Amprenavir phosphate.